Quest Diagnostics has licensed Matrix-Bio’s biomarkers for breast cancer recurrence and plans to launch a commercial diagnostic test in early 2015.
We’re developing a colon cancer monitoring test using metabolite profiling that detects cancer recurrence earlier and more accurately than existing tests.
Matrix-Bio seeks to raise $750,000 to validate our Colon Cancer Monitoring test (CCM), the first of three tests for the more than $2 billion colon cancer testing market.
Matrix-Bio CEO Eric Beier is a featured presenter at the 2014 Venture Summit West February 13 in Mountain View, Calif., seeking funding for new colon cancer tests.
Register for Updates
If you’re an investor or an oncologist interested in tracking Matrix-Bio’s progress, we invite your interest.
New molecular diagnostics such as DNA, RNA, and proteomics have not delivered the clinically actionable results envisioned. So why is metabolite profiling different?